Pesquisar
United Therapeutics Corp
UTHRAdicionar à lista de desejos
564.940USD
-4.240-0.74%
Fechamento 05/08, 16:00（ET）Cotações atrasadas em 15 min
23.98BValor de mercado
19.30P/L TTM
Mais detalhes de United Therapeutics Corp Empresa
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Informações de United Therapeutics Corp
Código da empresaUTHR
Nome da EmpresaUnited Therapeutics Corp
Data de listagemJun 17, 1999
CEORothblatt (Martine A)
Número de funcionários1305
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 17
Endereço1000 Spring St
CidadeSILVER SPRING
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20910
Telefone13016089292
Sitehttps://www.unither.com/
Código da empresaUTHR
Data de listagemJun 17, 1999
CEORothblatt (Martine A)
Executivos da empresa United Therapeutics Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
706.80K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
45.11K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+5.78%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.29K
-3.54%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.68%
Mr. Christopher Patusky, J.D.
Mr. Christopher Patusky, J.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
2.59K
--
Ms. Jan Malcolm
Ms. Jan Malcolm
Director
Director
125.00
-76.00%
Mr. Raymond C. (Ray) Kurzweil, J.D.
Mr. Raymond C. (Ray) Kurzweil, J.D.
Independent Director
Independent Director
--
--
Mr. Christopher A. Causey
Mr. Christopher A. Causey
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
706.80K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
45.11K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+5.78%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.29K
-3.54%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.68%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Tyvaso DPI
1.29B
40.59%
Nebulized Tyvaso
585.70M
18.40%
Remodulin
526.80M
16.55%
Orenitram
496.90M
15.61%
Unituxin
226.80M
7.13%
Outro
54.70M
1.72%
Por RegiãoUSD
Nome
Receita
Proporção
United States
3.04B
95.42%
Rest of World
145.70M
4.58%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Tyvaso DPI
1.29B
40.59%
Nebulized Tyvaso
585.70M
18.40%
Remodulin
526.80M
16.55%
Orenitram
496.90M
15.61%
Unituxin
226.80M
7.13%
Outro
54.70M
1.72%
Distribuição de ações
Atualizado em: há 23 horas
Atualizado em: há 23 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
9.75%
Avoro Capital Advisors LLC
6.14%
Wellington Management Company, LLP
5.75%
Vanguard Portfolio Management, LLC
4.72%
Vanguard Capital Management, LLC
4.61%
Outro
69.03%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
9.75%
Avoro Capital Advisors LLC
6.14%
Wellington Management Company, LLP
5.75%
Vanguard Portfolio Management, LLC
4.72%
Vanguard Capital Management, LLC
4.61%
Outro
69.03%
Tipos de investidores
Investidores
Proporção
Investment Advisor
52.01%
Investment Advisor/Hedge Fund
39.53%
Hedge Fund
10.32%
Pension Fund
2.92%
Research Firm
2.44%
Individual Investor
2.04%
Bank and Trust
1.48%
Sovereign Wealth Fund
1.45%
Venture Capital
0.38%
Participação acionária institucional
Atualizado em: dom, 5 de abr
Atualizado em: dom, 5 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
1548
42.91M
101.10%
-1.41M
2025Q4
1455
42.49M
98.68%
-3.10M
2025Q3
1348
44.10M
102.42%
-3.87M
2025Q2
1338
46.42M
102.62%
-2.51M
2025Q1
1369
46.67M
103.49%
-1.81M
2024Q4
1344
46.07M
102.60%
-3.00M
2024Q3
1278
45.38M
101.97%
-7.63M
2024Q2
1219
48.02M
108.26%
-2.92M
2024Q1
1151
47.12M
106.59%
-2.41M
2023Q4
1127
46.52M
99.01%
-2.26M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
4.14M
9.44%
-123.90K
-2.91%
Dec 31, 2025
Avoro Capital Advisors LLC
2.61M
5.95%
+583.84K
+28.87%
Dec 31, 2025
Wellington Management Company, LLP
2.44M
5.57%
+1.04M
+74.54%
Dec 31, 2025
Renaissance Technologies LLC
1.91M
4.36%
-264.13K
-12.15%
Dec 31, 2025
State Street Investment Management (US)
1.84M
4.2%
-80.20K
-4.17%
Dec 31, 2025
AQR Capital Management, LLC
1.28M
2.92%
+295.22K
+29.93%
Dec 31, 2025
Geode Capital Management, L.L.C.
1.19M
2.72%
-56.60K
-4.53%
Dec 31, 2025
Janus Henderson Investors
796.10K
1.82%
+341.38K
+75.08%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Simplify Health Care ETF
5.9%
Formidable Fortress ETF
4.22%
Franklin Genomic Advancements ETF
4.09%
First Trust NASDAQ Pharmaceuticals ETF
3.87%
Invesco Pharmaceuticals ETF
3.85%
Invesco Biotechnology & Genome ETF
3.82%
Invesco S&P MidCap Quality ETF
3.74%
Inspire Growth ETF
3.7%
VanEck Biotech ETF
3.58%
First Trust NYSE Arca Biotechnology Index Fund
3.4%
Ver Mais
Simplify Health Care ETF
Proporção5.9%
Formidable Fortress ETF
Proporção4.22%
Franklin Genomic Advancements ETF
Proporção4.09%
First Trust NASDAQ Pharmaceuticals ETF
Proporção3.87%
Invesco Pharmaceuticals ETF
Proporção3.85%
Invesco Biotechnology & Genome ETF
Proporção3.82%
Invesco S&P MidCap Quality ETF
Proporção3.74%
Inspire Growth ETF
Proporção3.7%
VanEck Biotech ETF
Proporção3.58%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.4%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
